Related Experiment Videos
Immunotherapy of habitual abortion
H J Carp1, V Toder, S Mashiach
1Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.
Summary
Immunotherapy using paternal leukocytes or immunoglobulin may improve live birth rates in women with recurrent miscarriages. Antipaternal complement-dependent antibody (APCA) production indicates a positive immune response and correlates with successful pregnancy outcomes.
Area of Science:
- Reproductive Immunology
- Obstetrics and Gynecology
Background:
- Habitual abortion is often linked to maternal hyporesponsiveness to paternal antigens.
- Paternal leukocyte immunization and immunoglobulin therapy are controversial treatments for recurrent miscarriages.
Purpose of the Study:
- To evaluate the efficacy of immunotherapy for habitual abortion.
- To investigate antipaternal complement-dependent antibody (APCA) as a marker for treatment success.
Main Methods:
- Analysis of patient outcomes following immunotherapy (paternal leukocyte immunization or immunoglobulin).
- Monitoring of antipaternal complement-dependent antibody (APCA) production as an indicator of immune response.
- Comparison of live birth rates in treated patients versus a control group, particularly in cases of multiple prior abortions.
Main Results:
- Immunotherapy resulted in live births in 80% of patients.
- Patients with five or more prior abortions had a 66% normal pregnancy rate post-treatment, compared to 20% in controls.
- Antipaternal complement-dependent antibody (APCA) production correlated with improved pregnancy outcomes.
Conclusions:
- Immunotherapy appears effective in improving live birth rates for habitual abortion.
- Antipaternal complement-dependent antibody (APCA) serves as a reliable marker for successful immunotherapy.
- Ongoing meta-analysis aims to definitively resolve the controversy surrounding immunotherapy efficacy.